Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Reason given: The research and development strategy was adjusted, so the research was suspended
Key facts
- Where
- Anyang, Beijing, Changde, Chongqing, Datong, Guangdong, Heilongjiang, Hunan, Jiangxi, Jilin City, Luoyang, Shanghai, Sichuan, Xinjiang, Xinxiang, and Yibin, ChinaSee the 17 sites
- Phase
- Phase 2
Where in China
- Anyang Tumor HospitalAnyang, ChinaNo longer taking part
- Beijing chest hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
- The First People's Hospital of ChangdeChangde, ChinaNo longer taking part
- Army Medical Center, PLAChongqing, ChinaNo longer taking part
- Second Affiliated Hospital, PLA Academy of Military Medical SciencesChongqing, ChinaNo longer taking part
- The Third People's Hospital of DatongDatong, ChinaNo longer taking part
- The First Affiliated Hospital of Guangzhou Medical UniversityGuangdong, ChinaNo longer taking part
- Harbin medical university cancer hospitalHeilongjiang, ChinaNo longer taking part
- Hunan Cancer HospitalHunan, ChinaNo longer taking part
- The First Affiliated Hospital of Nanchang UniversityJiangxi, ChinaNo longer taking part
- Jilin Cancer HospitalJilin City, ChinaNo longer taking part
- The First Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaNo longer taking part
- Shanghai Pulmonary HospitalShanghai, ChinaNo longer taking part
- West China Hospital，Sichuan UniversitySichuan, ChinaNo longer taking part
- Affiliated Tumor Hospital of Xinjiang Medical UniversityXinjiang, ChinaNo longer taking part
- The First Affiliated Hospital of Xinxiang Medical UniversityXinxiang, ChinaNo longer taking part
- Yibin Second People's HospitalYibin, ChinaNo longer taking part
Trial details
- Who runs it
- Shanghai Junshi Bioscience Co., Ltd.
- Trial code
- NCT06924606
- Record updated
- 25 September 2026
- Original description
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.Read full original descriptionShow less
A Phase II Study of JS207 (PD-1/VEGF Dual Antibody) in Combination With or Without JS004 or Docetaxel in Advanced Non-small Cell Lung Cancer With Disease Progression During or After the Treatment of Platinum-based Chemotherapy and Immunotherapy
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
Inclusion: Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) NSCLC that is not amenable to radical surgery or radical radiochemotherapy, or Metastatic or recurrent NSCLC; Subjects with unresectable locally advanced or metastatic or recurrent NSCLC who have failed first-line treatment with PD-1/PD-L1 inhibitors combined with platinum-based doublet chemotherapy (excluding docetaxel); or who have failed sequential first- and second-line treatment with PD-1/PD-L1 inhibitors followed by platinum-based doublet chemotherapy (excluding docetaxel); Subjects must have at least one measurable lesion according to RECIST v1.1.
Exclusion: Tumor encircles important blood vessels or has obvious necrosis and air space, and the investigator considers that it may cause hemorrhage risk; Sensitivity mutation of EGFR or ALK fusion; Histopathologically or cytopathologically confirmed to have combined neuroendocrine component.